ATXS News and Press, Astria Therapeutics Inc. From 04/19/23

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief...

2023-03-22 12:59:03 ET Astria Therapeutics, Inc. (ATXS) Q4 2022 Earnings Conference Call March 22, 2023 08:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientifi...

2023-03-22 10:48:10 ET The following slide deck was published by Astria Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Astria Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-22 08:03:51 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q4 GAAP EPS of -$0.72 misses by $0.01 . As of December 31, 2022, Astria had cash, cash equivalents, and short-term investments of $226.4 million, compared to $116.6 million as of September 30, 2...

-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215’s Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ende...

Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results be...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a c...

Gainers: OncoSec Medical ( ONCS ) +44% . BioRestorative Therapies BRTX +32% . Astria Therapeutics ( ATXS ) +13% . Certara ( CERT ) +12% . Kazia Therapeutics ( KZIA ) +11% . Losers: ZimVie ( ZIMV ) -45% . Cano Health ( CAN...

-- Additional Phase 1a Clinical Data Shows STAR-0215 Has Estimated Half-Life of up to 117 Days, Supporting Potential for Dosing Once Every Three Months or Less Frequently -- -- STAR-0215 Differentiated Plasma Kallikrein Binding is Consistent with High Specificity -- Astria The...

Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...